A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Bicalutamide (CASODEX)

Androgen Receptor Inhibitor class · 6 generic manufacturers · 6 ANDAs filed at FDA.

First FDA approval1995-10-04
Generic availableYes · 6 mfrs
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$10.9M in CY2024 Part D spend310K claims · 123K beneficiaries · 329 plans surveyed

Lowest NADAC
$0.403/unit
5 NDCs benchmarked, lowest of all strengths.
Average NADAC
$0.403
Across all dosage forms in distribution.
Highest NADAC
$0.403
Range is tight.
Plans with PA
0 / 329
Zero PA friction — switching is purely formulary.

Questions a plan sponsor actually asks.

FAQPage schema11 entries indexed · 4 visible
What is Bicalutamide used for?

Bicalutamide is a Androgen Receptor Inhibitor medication tracked in Medicare Part D.

Is there a generic for Bicalutamide?

Yes. 6 ANDAs filed at FDA, 6 generic manufacturers currently shipping.

How much does my plan pay for Bicalutamide?

Across 329 Part D plans, Bicalutamide averages $0.403/unit (NADAC). Lowest available: $0.403/unit. Highest in distribution: $0.403/unit.

Is Bicalutamide on the FDA shortage list?

No. Bicalutamide is not currently on the FDA Drug Shortage Database.

7 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Same class. Different math.

Androgen Receptor Inhibitor4 alternatives in D1
01
Clascoterone
Brand: Winlevi
$9.99Lowest NADAC
0Generic mfrs
$1.7MCY24 Part D spend
Compare →
02
Enzalutamide
Brand: Xtandi
Lowest NADAC
0Generic mfrs
$5.84BCY24 Part D spend
Compare →
03
Flutamide
Brand: Eulexin
Lowest NADAC
1Generic mfrs
$216,500CY24 Part D spend
Compare →
04
Nilutamide
Brand: Nilandron
Lowest NADAC
1Generic mfrs
$1.4MCY24 Part D spend
Compare →

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (7 approvals on file) · NADAC unit costs: CMS NADAC weekly file (5 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.